Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $99.00 to $103.00. They now have an "outperform" rating on the stock.
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan [Yahoo! Finance]
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Cytokinetics and Bayer partner to develop for aficamten in Japan [Seeking Alpha]
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan [Yahoo! Finance]